1 - 9 out of 9Page size: 10
  1. 2023

  2. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV

    Verburgh, M. L., van Pul, L., Grobben, M., Boyd, A., Wit, F. W. N. M., van Nuenen, A. C., van Dort, K. A., Tejjani, K., van Rijswijk, J., Bakker, M., van der Hoek, L., Schim van der Loeff, M. F., van der Valk, M., van Gils, M. J., Kootstra, N. A. & Reiss, P., 11 May 2023, (E-pub ahead of print) In: Microbiology spectrum. p. e0115523

    Research output: Contribution to journal › Article › Academic › peer-review

  3. 2022

  4. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection

    Brouwer, P. J. M., Antanasijevic, A., Ronk, A. J., Müller-Kräuter, H., Watanabe, Y., Claireaux, M., Perrett, H. R., Bijl, T. P. L., Grobben, M., Umotoy, J. C., Schriek, A. I., Burger, J. A., Tejjani, K., Lloyd, N. M., Steijaert, T. H., van Haaren, M. M., Sliepen, K., de Taeye, S. W., van Gils, M. J., Crispin, M., & 4 othersStrecker, T., Bukreyev, A., Ward, A. B. & Sanders, R. W., 14 Dec 2022, In: Cell host & microbe. 30, 12, p. 1759-1772.e12

    Research output: Contribution to journal › Article › Academic › peer-review

  5. A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike

    van der Velden, Y. U., Grobben, M., Caniels, T. G., Burger, J. A., Poniman, M., Oomen, M., Rijnstra, E. S., Tejjani, K., Guerra, D., Kempers, R., Stegmann, T., van Gils, M. J. & Sanders, R. W., 1 Dec 2022, In: Scientific reports. 12, 1, 3884.

    Research output: Contribution to journal › Article › Academic › peer-review

  6. Older people with well-controlled HIV have similar antibody and higher T-cell responses after vaccination against SARS-CoV-2 compared to demographically and lifestyle-comparable people without HIV

    Verburgh, M., van Pul, L., Grobben, M., Boyd, A., Wit, F., van Nuenen, A., van Dort, K., Tejjani, K., van Rijswijk, J., Bakker, M., van der Hoek, L., van der Loeff, M. S., van der Valk, M., van Gils, M., Kootstra, N. & Reiss, P., 1 Oct 2022, In: Journal of the International AIDS Society. 25, 6, SI, p. 7-9 3 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  7. Differences in systemic and mucosal SARS-CoV-2 antibody prevalence in a prospective cohort of Dutch children

    Keuning, M. W., Grobben, M., Bijlsma, M. W., Anker, B., Berman-de Jong, E. P., Cohen, S., Felderhof, M., de Groen, A-E., de Groof, F., Rijpert, M., van Eijk, H. W. M., Tejjani, K., van Rijswijk, J., Steenhuis, M., Rispens, T., Plötz, F. B., van Gils, M. J. & Pajkrt, D., 9 Sept 2022, In: Frontiers in immunology. 13, 976382.

    Research output: Contribution to journal › Article › Academic › peer-review

  8. Decreased Passive Immunity to Respiratory Viruses through Human Milk during the COVID-19 Pandemic

    Grobben, M., Juncker, H. G., van der Straten, K., Lavell, A. H. A., Schinkel, M., Buis, D. T. P., Wilbrink, M. F., Tejjani, K., Claireaux, M. A. F., Aartse, A., de Groot, C. J. M., Pajkrt, D., Bomers, M. K., Sikkens, J. J., van Gils, M. J., van Goudoever, J. B. & van Keulen, B. J., 31 Aug 2022, In: Microbiology spectrum. 10, 4, p. e0040522

    Research output: Contribution to journal › Article › Academic › peer-review

  9. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study

    van Gils, M. J., Lavell, A., van der Straten, K., Appelman, B., Bontjer, I., Poniman, M., Burger, J. A., Oomen, M., Bouhuijs, J. H., van Vught, L. A., Slim, M. A., Schinkel, M., Wynberg, E., van Willigen, H. D. G., Grobben, M., Tejjani, K., van Rijswijk, J., Snitselaar, J. L., Caniels, T. G., Vlaar, A. P. J., & 6 othersPrins, M., de Jong, M. D., de Bree, G. J., Sikkens, J. J., Bomers, M. K. & Sanders, R. W., 1 May 2022, In: PLoS medicine. 19, 5, e1003991.

    Research output: Contribution to journal › Article › Academic › peer-review

  10. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

    van Gils, M. J., van Willigen, H. D. G., Wynberg, E., Han, A. X., van der Straten, K., Burger, J. A., Poniman, M., Oomen, M., Tejjani, K., Bouhuijs, J. H., Verveen, A., Lebbink, R., Dijkstra, M., Appelman, B., Lavell, A. H. A., Caniels, T. G., Bontjer, I., van Vught, L. A., Vlaar, A. P. J., Sikkens, J. J., & 32 othersBomers, M. K., Russell, C. A., Kootstra, N. A., Sanders, R. W., Prins, M., de Bree, G. J., de Jong, M. D., RECoVERED Study Group, Agard, I., Ayal, J., Boyd, A., Cavdar, F., Craanen, M., Davidovich, U., Deuring, A., van Dijk, A., Ersan, E., del Grande, L., Hartman, J., Koedoot, N., van den Aardweg, J., Boeser-Nunnink, B., Moll van Charante, E., van Dort, K., Hidad, S., Jurriaans, S., Knoop, H., Lok, A., Maurer, I., Nieuwkerk, P., van Nuenen, A. & Matser, A., 18 Jan 2022, In: Cell Reports Medicine. 3, 1, 100486.

    Research output: Contribution to journal › Article › Academic › peer-review

  11. 2021

  12. Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination

    Amsterdam UMC COVID-19 S3/HCW study group, 1 Oct 2021, In: EBioMedicine. 72, 103589.

    Research output: Contribution to journal › Article › Academic › peer-review

ID: 14469371